Business Context and Reporting Period
Company: Intellia Therapeutics, Inc. (NTLA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Intellia is a clinical-stage biopharmaceutical company developing CRISPR-based in vivo genome editing therapies. Its lead candidates are lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis. The company is preparing for a potential commercial launch of lonvo-z in the first half of 2027.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $67.7 | $57.9 |
| Research & Development Expenses | $388.9 | $466.3 |
| General & Administrative Expenses | $119.8 | $125.8 |
| Net Loss | $(412.7) | $(519.0) |
| Cash, Cash Equivalents & Marketable Securities | $605.1 | $601.5 |
| Accumulated Deficit | $(2,590.1) | $(2,177.4) |
Liquidity: As of December 31, 2025, the company held $605.1 million in cash, cash equivalents, and marketable securities. Management expects these resources, combined with collaboration funding, to fund operations into the second half of 2027.
Material Changes vs. Prior Period
- Revenue Growth: Collaboration revenue increased by $9.8 million (17%) to $67.7 million, driven by a $23.7 million increase in cost reimbursements from Regeneron and $9.0 million recognized from the termination of the SparingVision agreement.
- Expense Reduction: Total operating expenses decreased by $83.5 million. R&D expenses dropped $77.5 million, primarily due to a $28.7 million reduction in employee-related expenses (following a January 2025 workforce reduction) and a $44.8 million decrease in stock-based compensation.
- Net Loss Improvement: Net loss narrowed by $106.3 million to $412.7 million, reflecting lower operating costs and a $31.7 million improvement in the change in fair value of investments.
- Real Estate Restructuring: The company executed a strategic restructuring involving the termination of its 840 Winter Street lease and the commencement of a new lease at 400 Technology Square, resulting in $6.2 million in accelerated amortization and impairment charges.
Guidance, Outlook, Risks, and Unusual Items
Clinical Program Status & Outlook
- Lonvo-z (HAE): Enrollment in the global Phase 3 HAELO trial was completed in September 2025 with 80 patients. Topline data is expected by mid-2026, with a potential BLA filing in late 2026 and U.S. launch in H1 2027.
- Nex-z (ATTR): The FDA placed a clinical hold on the MAGNITUDE (ATTR-CM) and MAGNITUDE-2 (ATTRv-PN) Phase 3 trials in October 2025 following a patient death and Grade 4 liver transaminase elevations. The hold on MAGNITUDE-2 was lifted in January 2026; the hold on MAGNITUDE remains in place as the company engages with the FDA.
Key Risks and Contingencies
- Regulatory Uncertainty: The ongoing clinical hold on the MAGNITUDE trial poses a significant risk to the development timeline of nex-z. Resolution is required to resume dosing.
- Intellectual Property Litigation: BlueAllele Corp. filed a patent infringement lawsuit in July 2024 regarding bi-directional insertion template technology. The company filed counterclaims, and discovery is ongoing.
- Securities Litigation: A putative class-action lawsuit (Gonzalez v. Intellia Therapeutics, Inc.) alleges false statements regarding the NTLA-3001 program. A motion to dismiss is pending.
- Patent Interferences: Ongoing interferences at the PTAB involving the Broad Institute, ToolGen, and Sigma-Aldrich regarding foundational CRISPR patents could impact the company's freedom to operate.
Unusual Items
- Investment Impairment: The company recognized a $7.5 million loss on its investment in SparingVision following the termination of their collaboration agreement in October 2025.
- Restructuring Costs: Approximately $65.0 million in non-recurring cash payments were made in 2025 related to portfolio prioritization, workforce reduction, and real estate consolidation.
Investor Verification Checklist
- Clinical Hold Resolution: Monitor updates on the FDA clinical hold for the MAGNITUDE Phase 3 trial (nex-z) and the timeline for resuming dosing.
- HAELO Trial Data: Verify the timing and results of the topline data release for the lonvo-z Phase 3 trial (expected mid-2026).
- Litigation Status: Track the progress of the BlueAllele patent infringement case and the Gonzalez securities class action.
- Cash Burn Rate: Assess the sustainability of the $605.1 million cash position against the projected runway into H2 2027, considering potential delays in nex-z development.
- Regulatory Milestones: Confirm the status of the BLA filing for lonvo-z and any potential regulatory interactions regarding the safety profile of nex-z.